Chesterford Research Park is delighted to announce the expansion of an existing occupier, SuperDielectrics, into new laboratory and write up space within the Emmanuel Building.
Superdielectrics first moved to Chesterford Research Park in February this year, taking a suite in the multi-occupancy Science Village building. Due to the accelerated development of its proprietary technology, the organisation required the ability to scale-up swiftly and the newly completed Emmanuel Building at the Park provided the ideal opportunity at the right time.
The Emmanuel Building is the latest building to undergo a complete refurbishment at Chesterford Research Park. Completed in August this year it provides a total of 37,400 sq ft (3,474 sq m) of fitted laboratory space divided into four self-contained laboratory and write-up area suites. Ideal for organisations which are scaling up, the Emmanuel Building has seen unprecedented demand, which will result in further new occupier announcements in the coming weeks.
Superdielectrics’ mission is to develop high energy density, low cost, low environmental impact electrical energy storage devices that will help create a clean and sustainable global energy and transportation system. Superdielectric’s storage devices (supercapacitors) are not only safe, rapidly rechargeable and have a long life, they contain no rare materials or conflict metals and have the added benefit of reducing pollution and waste with no end-of-life recycling issues.
Jim Heathcote, CEO, Superdielectrics said: “Over the past six months Superdielectrics has made great progress developing electricity storage technology for the clean and sustainable 21st century energy system. Our landlords and the Chesterford Research Park management team recognise the global importance of our work and have been extraordinarily supportive. Our expansion into the Emmanuel Building reflects the support we have received and our shared environmental values.”
Julian Cobourne, Head of Regional Offices, Aviva Investors, joint owners of Chesterford Research Park with Uttlesford District Council added: “It is always incredibly exciting to see our occupiers go from strength to strength, and particularly satisfying to be able to support their development and expansion via the provision of further facilities within our own Park environment. We have worked closely with the Superdielectrics team to understand their requirements and the trajectory of their research and I am therefore delighted that they will be continuing the development of their ground-breaking work with us.
“The completion of the refurbishment of the Emmanuel Building and subsequent strong response from both current occupiers and other organisations - both within the Cambridge cluster and beyond – has enabled us to look forward to the next phase of development at Chesterford Research Park, namely a 60,000 sq ft multi-occupier building, fitted with a mix of laboratory and office space. Subject to planning, this next building will be ready for occupation by the end of 2023.”
Chesterford Research Park provides an exceptional environment for biotechnology and pharmaceutical organisations at start-up, scale-up and beyond. Innovative and future-proof laboratory and office spaces combine within the stunning parkland setting to create an environment in which life science research and development thrives. It is this mix of facilities, unique setting and an expert, on-hand Park management team that continues to attract technology and life science innovators including Arecor, AstraZeneca, Lonza, Charles River Laboratories, Domainex, Microbiotica and Mestag Therapeutics.
Park owners Aviva Investors and Uttlesford District Council are advised by Chesterford Research Park’s joint commercial agents, Savills and Cheffins.